Liver cancer drug combo study halted early
NCT ID NCT05220722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to deliver an immune-boosting drug (SD-101) directly into the liver along with standard immunotherapy for people with advanced liver cancer. It included 23 adults whose cancer had not responded to prior treatment. The goal was to find a safe dose and see if the combination could shrink tumors. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University
New York, New York, 10032, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver